Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Cited by (1,024)

Items 101–200 of 1,024

1. Role of the renin–angiotensin system in vascular inflammation
   Marchesi, Chiara, Paradis, Pierre, Schiffrin, Ernesto L. · 2008 · Trends in Pharmacological Sciences
2. Sirtuins — novel therapeutic targets to treat age-associated diseases
   Siva Lavu, Olivier Boss, Peter J. Elliott, Philip Lambert · 2008 · Nature Reviews Drug Discovery
3. Activation of a HIF1α-PPARγ Axis Underlies the Integration of Glycolytic and Lipid Anabolic Pathways in Pathologic Cardiac Hypertrophy
   Jaya Krishnan, Marianne Suter, Renata Windak, Tatiana Krebs, Allison Felley, Christophe Montessuit, Małgorzata Tokarska-Schlattner, Ellen Aasum, Anna Y. Bogdanova, Evelyne R. Perriard et al. · 2009 · Cell Metabolism
4. Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association
   Rodica Pop‐Busui, James L. Januzzi, Dennis Bruemmer, Sonia Butalia, Jennifer B. Green, William B. Horton, Colette M. Knight, Moshe Levi, Neda Rasouli, Caroline Regina Richardson · 2022 · Diabetes Care
5. Trial Publication after Registration in ClinicalTrials.Gov: A Cross-Sectional Analysis
   Ross, Joseph S., Mulvey, Gregory K., Hines, Elizabeth M., Nissen, Steven E., Krumholz, Harlan M. · 2009 · PLoS Medicine
6. Targeting fatty acid and carbohydrate oxidation — A novel therapeutic intervention in the ischemic and failing heart
   Jagdip S. Jaswal, Wendy Keung, Wei Wang, John R. Ussher, Gary D. Lopaschuk · 2011 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
7. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
   Griffin, Simon J., Leaver, James K., Irving, Greg J. · 2017 · Diabetologia
8. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
   Tahrani, Abd A., Barnett, Anthony H., Bailey, Clifford J. · 2016 · Nature Reviews Endocrinology
9. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy
   James E. McLaren, Daryn R. Michael, Tim G. Ashlin, Dipak P. Ramji · 2011 · Progress in Lipid Research
10. Partial Agonists Activate PPARγ Using a Helix 12 Independent Mechanism
    John B. Bruning, Michael J. Chalmers, Swati Prasad, Scott A. Busby, Theodore M. Kamenecka, Yuanjun He, K.W. Nettles, Patrick R. Griffin · 2007 · Structure
11. Thiazolidinediones and PPARγ agonists: time for a reassessment
    Bertrand Cariou, Bernard H. Charbonnel, Bart Staels · 2012 · Trends in Endocrinology and Metabolism
12. Thiazolidinediones: the forgotten diabetes medications
    Lebovitz, Harold E. · 2019 · Current Diabetes Reports
13. Compliance with Results Reporting at ClinicalTrials.gov
    Anderson, Monique L., Chiswell, Karen, Peterson, Eric D., Tasneem, Asba, Topping, James, Califf, Robert M. · 2015 · New England Journal of Medicine
14. Intensive Glycemic Control in the ACCORD and ADVANCE Trials
    Robert George Dluhy, Graham T. McMahon · 2008 · New England Journal of Medicine
15. An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus
    Ahlke Heydemann · 2016 · Journal of Diabetes Research
16. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes
    Floris A Van de Laar · 2008 · Vascular Health and Risk Management
17. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
    William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, Jay S. Skyler, Jennifer B. Green, John B. Buse, Silvio E. Inzucchi, Lawrence A. Leiter et al. · 2017 · Diabetes Care
18. Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use
    S. Swaroop Vedula, Lisa Anne Bero, Roberta W. Scherer, Kay Dickersin · 2009 · New England Journal of Medicine
19. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
    Dean T. Eurich, Finlay Aleck McAlister, David F Blackburn, Sumit R. Majumdar, Ross T. Tsuyuki, Janice Varney, Jeffrey A. Johnson · 2007 · BMJ
20. Systematic review: glucose control and cardiovascular disease in type 2 diabetes
    Kelly, Tanika N., Bazzano, Lydia A., Fonseca, Vivian A., Thethi, Tina K., Reynolds, Kristi, He, Jiang · 2009 · Annals of Internal Medicine
21. Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
    Shan Zhao, Ravi Iyengar · 2011 · The Annual Review of Pharmacology and Toxicology
22. Diagnosis and Therapy of Nonalcoholic Steatohepatitis
    Dawn McDowell Torres, Stephen A. Harrison · 2008 · Gastroenterology
23. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials
    Nigel A. Calcutt, Mark Emmanuel Cooper, Tim S Kern, Ann Marie Schmidt · 2009 · Nature Reviews Drug Discovery
24. Insulin-Resistant Cardiomyopathy
    Ronald M. Witteles, Michael B. Fowler · 2008 · Journal of the American College of Cardiology
25. Nonalcoholic Fatty Liver Disease: A Review and Update
    Jeffrey R. Lewis, Smruti R. Mohanty · 2010 · Digestive Diseases and Sciences
26. Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
    Lorraine Lucille Lipscombe, Tara Gomes, Linda E. Lévesque, Janet E. Hux, David Nelson Juurlink, David Andrew Alter · 2007 · JAMA
27. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes
    Ebenezer A. Nyenwe, Terri W. Jerkins, Guillermo E. Umpierrez, Abbas E. Kitabchi · 2010 · Metabolism
28. Atherosclerotic Plaque Destabilization
    Carlos Silvestre-Roig, Menno P.J. de Winther, Christian Weber, Mat J.A.P. Daemen, Esther Lutgens, Oliver Soehnlein · 2014 · Circulation Research
29. FABP4 Attenuates PPARγ and Adipogenesis and Is Inversely Correlated With PPARγ in Adipose Tissues
    Tali Garin-Shkolnik, Assaf Rudich, Gökhan S. Hotamışlıgil, Menachem Rubinstein · 2013 · Diabetes
30. Metabolomics Applied to Diabetes Research
    James Ralph Bain, Robert D. Stevens, Brett R. Wenner, Olga Ilkayeva, Deborah M. Muoio, Christopher B. Newgard · 2009 · Diabetes
31. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
    Briohny W. Smith, Leon Anton Adams · 2011 · Nature Reviews Endocrinology
32. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
    David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin, Bernard Zinman · 2007 · Diabetes Care
33. PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
    Hao Chen, Huabing Tan, Juan Wan, Yong Zeng, Jincheng Wang, Haichuan Wang, Xiaojie Lu · 2023 · Pharmacology & Therapeutics
34. High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial†
    Leuschner, Ulrich F. H., Lindenthal, Birgit, Herrmann, Günter, Arnold, Joachim C., Rössle, Martin, Cordes, Hans‐Jörg, Zeuzem, Stefan, Hein, Jasper, Berg, Thomas · 2010 · Hepatology
35. Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose
    Ralph A. DeFronzo, Muhammad A Abdul‐Ghani · 2011 · The American Journal of Cardiology
36. Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
    Ralph Anthony DeFronzo, Roy Eldor, Muhammad A Abdul‐Ghani · 2013 · Diabetes Care
37. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
    Francque, Sven, Szabo, Gyongyi, Abdelmalek, Manal F., Byrne, Christopher D., Cusi, Kenneth, Dufour, Jean-François, Roden, Michael, Sacks, Frank, Tacke, Frank · 2021 · Nature Reviews Gastroenterology & Hepatology
38. Misunderstandings about Q and ‘Cochran's Q test' in meta‐analysis
    David C. Hoaglin · 2015 · Statistics in Medicine
39. A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials
    Gayvert, Kaitlyn M., Madhukar, Neel S., Elemento, Olivier · 2016 · Cell chemical biology
40. The gait and balance of patients with diabetes can be improved: a randomised controlled trial
    Lara Allet, Stéphane Armand, Rob A. de Bie, Alain Golay, Dominique Monnin, Kamiar Aminian, J. Bart Staal, Eling Douwe de Bruin · 2009 · Diabetologia
41. A review of the efficacy and safety of oral antidiabetic drugs
    Stephanie Aleskow Stein, Elizabeth Mary Lamos, Stephen N. Davis · 2012 · Expert Opinion on Drug Safety
42. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association
    Arnold, Suzanne V., Bhatt, Deepak L., Barsness, Gregory W., Beatty, Alexis L., Deedwania, Prakash C., Inzucchi, Silvio E., Kosiborod, Mikhail, Leiter, Lawrence A., Lipska, Kasia J., Newman, Jonathan D. et al. · 2020 · Circulation
43. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored
    John J.V. McMurray, Hertzel C. Gerstein, Rury R. Holman, Marc Alan Pfeffer · 2014 · The Lancet Diabetes & Endocrinology
44. Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus
    Christianne L. Roumie, Adriana M. Hung, Robert A. Greevy, Carlos G. Grijalva, Xulei Liu, Harvey J. Murff, Tom A. Elasy, Marie R. Griffin · 2012 · Annals of Internal Medicine
45. Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
    Selvin, Elizabeth, Bolen, Shari, Yeh, Hsin-Chieh, Wiley, Crystal, Wilson, Lisa M., Marinopoulos, Spyridon S., Feldman, Leonard, Vassy, Jason, Wilson, Renee, Bass, Eric B. et al. · 2008 · Archives of Internal Medicine
46. Emerging Roles of Vascular Endothelium in Metabolic Homeostasis
    Xinchun Pi, Liang Xie, Cam Patterson · 2018 · Circulation Research
47. Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3/2011. Julian P.T. Higgins and Sally Green, Editors
    Shuster, Jonathan J. · 2011 · Research Synthesis Methods
48. Regulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
    Elena Rigamonti, Giulia Chinetti, Bart Staels · 2008 · Arteriosclerosis Thrombosis and Vascular Biology
49. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
    Richard E. Gilbert, Henry Krum · 2015 · The Lancet
50. High-Density Lipoprotein
    Thomas Felix Lüscher, Ulf Landmesser, Arnold von Eckardstein, Alan M. Fogelman · 2014 · Circulation Research
51. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations
    David Preiss, Naveed A. Sattar · 2008 · Clinical Science
52. Non-alcoholic fatty liver disease
    Briohny W. Smith, Leon Anton Adams · 2011 · Critical Reviews in Clinical Laboratory Sciences
53. Pharmacovigilance: methods, recent developments and future perspectives
    Linda Härmark, A.C. van Grootheest · 2008 · European Journal of Clinical Pharmacology
54. Treatment-effect estimates adjusted for small-study effects via a limit meta-analysis
    Gerta Rücker, Guido Schwarzer, James Robert Carpenter, Harald Binder, Martin Christian Schumacher · 2010 · Biostatistics
55. Uncertain Effects of Rosiglitazone on the Risk for Myocardial Infarction and Cardiovascular Death
    George A. Diamond, Leon Bax, Sanjay Kaul · 2007 · Annals of Internal Medicine
56. Adiponectin and cardiovascular health: an update
    Xiaoyan Hannah Hui, Karen SL Lam, Paul M. Vanhoutte, Aimin Xu · 2011 · British Journal of Pharmacology
57. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source
    Yoshihiro Noguchi, Tomoya Tachi, Hitomi Teramachi · 2021 · Briefings in Bioinformatics
58. Effect of non-oil-seed pulses on glycaemic control: a systematic review and meta-analysis of randomised controlled experimental trials in people with and without diabetes
    John L. Sievenpiper, Cyril W.C. Kendall, A. Esfahani, Josephine Wong, Amanda J. Carleton, H. Y. Jiang, Richard Paul Bazinet, Edward Vidgen, David J.A. Jenkins · 2009 · Diabetologia
59. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals
    Howard C. Masuoka, Naga Chalasani · 2013 · Annals of the New York Academy of Sciences
60. Exercise for the management of type 2 diabetes: a review of the evidence
    Silvano Zanuso, Alfonso Jiménez, Giuseppe Pugliese, Gerardo Corigliano, Stefano Balducci · 2009 · Acta Diabetologica
61. When good drugs go bad
    Kathleen M. Giacomini, Ronald M. Krauss, Dan M. Roden, Michel F Eichelbaum, Michael R. Hayden, Yusuke Nakamura · 2007 · Nature
62. PPARγ Agonists as Therapeutics for the Treatment of Alzheimer's Disease
    Gary E. Landreth, Qingguang Jiang, Shweta Mandrekar, Michael Thomas Heneka · 2008 · Neurotherapeutics
63. Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases
    Qian Yi Eng, Punniyakoti Thanikachalam Veeraveedu, S Ramamurthy · 2017 · Journal of Ethnopharmacology
64. Sodium Intake in Populations: Assessment of Evidence
    Brian L. Strom, Ann L. Yaktine, Maria P. Oria, Nutrition Board · 2013
65. Gliflozins in the Management of Cardiovascular Disease
    Eugene Braunwald · 2022 · New England Journal of Medicine
66. The replication of β cells in normal physiology, in disease and for therapy
    Butler, Peter C, Meier, Juris J, Butler, Alexandra E, Bhushan, Anil · 2007 · Nature Clinical Practice Endocrinology & Metabolism
67. Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
    Dawn McDowell Torres, Christopher David Williams, Stephen A. Harrison · 2012 · Clinical Gastroenterology and Hepatology
68. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
    Hong Sheng Cheng, Wei Tan, Zun Siong Low, Charlie Marvalim, Justin Yin Hao Lee, Nguan Soon Tan · 2019 · International Journal of Molecular Sciences
69. Obesity-induced Insulin Resistance and Hyperglycemia
    J. A. Jeevendra Martyn, Masao Kaneki, Shingo Yasuhara, David S. Warner, Mark A. A. Warner · 2008 · Anesthesiology
70. Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials
    Boussageon, Rémy, Supper, Irène, Bejan-Angoulvant, Theodora, Kellou, Nadir, Cucherat, Michel, Boissel, Jean-Pierre, Kassai, Behrouz, Moreau, Alain, Gueyffier, François, Cornu, Catherine · 2012 · PLoS Medicine
71. Pathogenesis and management issues for non-alcoholic fatty liver disease
    Marko Duvnjak · 2007 · World Journal of Gastroenterology
72. Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
    Meghan Sauvé, Kiwon Ban, M. Abdul Momen, Yuqing Zhou, R. Mark Henkelman, Mansoor Husain, Daniel J. Drucker · 2010 · Diabetes
73. β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes
    Saisho, Yoshifumi · 2015 · World Journal of Diabetes
74. Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
    Sheng Zhong Duan, Michael G. Usher, Richard M. Mortensen · 2008 · Circulation Research
75. The prevention of type 2 diabetes
    , for the Diabetes Prevention Program Research Group, Crandall, Jill P, Knowler, William C, Kahn, Steven E, Marrero, David, Florez, Jose C, Bray, George A, Haffner, Steven M, Hoskin, Mary, Nathan, David M · 2008 · Nature Clinical Practice Endocrinology & Metabolism
76. Management of blood glucose in type 2 diabetes mellitus.
    Cynthia M. Ripsin, Helen H. Kang, Randall J. Urban · 2009 · PubMed
77. Dipeptidyl peptidase‐4 inhibitors and cardiovascular risk: a meta‐analysis of randomized clinical trials
    Matteo Monami, Bo Åhrén, Ilaria Dicembrini, Edoardo Mannucci · 2012 · Diabetes Obesity and Metabolism
78. Highlights in Heart Failure
    Daniela Tomasoni, Marianna Adamo, Carlo Lombardi, Marco Metra · 2019 · ESC Heart Failure
79. Forgotten but Not Gone
    Lidia S. Szczepaniak, Ronald G. Victor, Lelio Orci, Roger H. Unger · 2007 · Circulation Research
80. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
    Debora Williams‐Herman, Samuel S. Engel, Elizabeth Round, Jeremy R. Johnson, Gregory T. Golm, Hua Guo, Bret J. Musser, Michael J. Davies, Keith D. Kaufman, Barry J. Goldstein · 2010 · BMC Endocrine Disorders
81. Lipodystrophy: pathophysiology and advances in treatment
    Christina G. Fiorenza, Sharon Hsiao-Han Chou, Christos Socrates Mantzoros · 2010 · Nature Reviews Endocrinology
82. PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
    Sugii, Shigeki, Olson, Peter, Sears, Dorothy D., Saberi, Maziyar, Atkins, Annette R., Barish, Grant D., Hong, Suk-Hyun, Castro, Glenda L., Yin, Yun-Qiang, Nelson, Michael C. et al. · 2009 · Proceedings of the National Academy of Sciences
83. Disruption of PPARγ/β-catenin–mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival
    Tero‐Pekka Alastalo, Molong Li, Vinicio de Jesús Pérez, David Pham, Hirofumi Sawada, Jordon K. Wang, Minna Koskenvuo, Lingli Wang, Bruce Α. Freeman, Howard Y. Chang et al. · 2011 · Journal of Clinical Investigation
84. PPAR Agonists and Metabolic Syndrome: An Established Role?
    Margherita Botta, Matteo Audano, Amirhossein Sahebkar, Cesare Riccardo Sirtori, Nico Mitro, Massimiliano Ruscica · 2018 · International Journal of Molecular Sciences
85. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta‐analysis with zero cells
    Gerta Rücker, Guido Schwarzer, James Robert Carpenter, Ingram Olkin · 2008 · Statistics in Medicine
86. Patient-Important Outcomes in Registered Diabetes Trials
    Gunjan Yogendra Gandhi · 2008 · JAMA
87. Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies
    Jennie H. Best, Byron J. Hoogwerf, William H. Herman, Elise M. Pelletier, Daniel B. Smith, Madé Wenten, Mohamed A. Hussein · 2010 · Diabetes Care
88. Beyond the Randomized Clinical Trial
    Brahmajee K. Nallamothu, Rodney A. Hayward, Eric Bates · 2008 · Circulation
89. Evaluating the Evidence
    P. Michael Ho, Pamela N. Peterson, Frederick A. Masoudi · 2008 · Circulation
90. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes
    Montvida, Olga, Shaw, Jonathan, Atherton, John J., Stringer, Frances, Paul, Sanjoy K. · 2018 · Diabetes Care
91. Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
    Matteo Monami, Stefano Genovese, Edoardo Mannucci · 2013 · Diabetes Obesity and Metabolism
92. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
    Salpeter, Shelley R., Buckley, Nicholas S., Kahn, Justin A., Salpeter, Edwin E. · 2008 · The American Journal of Medicine
93. Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology
    Christoph Maack, Michael Lehrke, Johannes Backs, Frank R. Heinzel, Jean‐Sébastien Hulot, Nikolaus Marx, Walter J. Paulus, Patrick Rossignol, Heinrich Taegtmeyer, Johann K Bauersachs et al. · 2018 · European Heart Journal
94. Interleukin-17: a mediator of inflammatory responses
    Janusz Witowski, Krzysztof Książek, Achim Jörres · 2004 · Cellular and Molecular Life Sciences
95. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
    Lorraine Lucille Lipscombe, Gillian L. Booth, Sonia Butalia, Kaberi Dasgupta, Dean T. Eurich, Ronald Goldenberg, Nadia Khan, Lori MacCallum, Baiju R. Shah, Scot H. Simpson · 2018 · Canadian Journal of Diabetes
96. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
    Yoon Kong Loke, Chun Shing Kwok, Sonal Singh · 2011 · BMJ
97. Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
    Steven P. Marso, Neil R Poulter, Steven E. Nissen, Michael Albrecht Nauck, Bernard Zinman, Gilbert H. Daniels, Stuart Pocock, William M. Steinberg, Richard M. Bergenstal, Johannes F.E. Mann et al. · 2013 · American Heart Journal
98. PPAR-α Modulators as Current and Potential Cancer Treatments
    Tiange Chi, Mina Wang, Xu Wang, Yang Ke, Fei Xie, Liao Zehuan, Peng Wei · 2021 · Frontiers in Oncology
99. The PPAR trio: Regulators of myocardial energy metabolism in health and disease
    José Madrazo, Daniel P. Kelly · 2008 · Journal of Molecular and Cellular Cardiology
100. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control
     Giulia Borghetti, Dirk von Lewinski, Deborah Eaton, Harald Sourij, Steven R. Houser, Markus Wallner · 2018 · Frontiers in Physiology